AMA Adopts Flavored Cannabis Vape Ban, Older Adult Use Resolution

House of Delegates Approves Dual Cannabis Measures

The AMA House of Delegates passed both resolutions during its June 2026 meeting, with the flavored-vape ban measure citing youth-access concerns and the geriatric-use resolution acknowledging a growing evidence base for older patients. The American Medical Association, which represents more than 270,000 physicians and medical students, has steadily refined its cannabis positions since 2019, when it dropped outright opposition to legalization in favor of evidence-based regulation.

The flavored-vape resolution directs AMA to advocate for federal and state bans on flavored cannabis vaping products, mirroring tobacco-flavoring restrictions enacted in multiple states. The older-adult resolution instructs AMA to develop educational materials for physicians treating geriatric patients who use or are considering cannabis.

Flavored Vape Ban Targets Youth Initiation Pathways

The resolution supporting a flavored cannabis vape ban cites data showing flavored products increase youth initiation rates and complicate age-verification enforcement. Delegates said fruit, candy, and dessert flavors market directly to adolescents. The argument echoes claims that drove FDA restrictions on flavored nicotine products in 2020.

California, Massachusetts, and New York already restrict flavored cannabis vapes through state law or regulatory action. The AMA resolution calls for uniform federal standards under any future cannabis rescheduling or legalization framework.

The medical group's position aligns it with public-health advocates who say flavor restrictions reduce underage consumption without materially limiting adult access to unflavored formulations.

Older Adult Resolution Balances Benefits and Drug Interactions

The geriatric-use resolution acknowledges cannabis may offer therapeutic benefits for chronic pain, sleep disorders, and appetite stimulation in older adults, while flagging risks including polypharmacy interactions, cognitive impairment, and fall hazards. Adults over 65 represent the fastest-growing segment of state medical cannabis programs, with enrollment rising 42 percent annually since 2022 according to data from 23 reporting states.

The resolution doesn't endorse cannabis as first-line therapy. Instead, it directs AMA to compile peer-reviewed evidence on cannabinoid pharmacology in geriatric populations. It also calls for physician education on drug-drug interactions between cannabis and common medications for hypertension, diabetes, and anticoagulation.

AMA's Evolving Cannabis Stance Since 2019

The June resolutions continue AMA's shift from prohibitionist orthodoxy to harm-reduction pragmatism. In 2019, the House of Delegates rescinded a decades-old policy opposing any legalization, replacing it with support for research access and evidence-based regulation. Subsequent resolutions have addressed impaired-driving standards, workplace drug testing, and pediatric epilepsy protocols.

The organization hasn't endorsed full federal legalization. But AMA supports rescheduling cannabis under the Controlled Substances Act to facilitate clinical trials. AMA submitted comments to DEA in 2024 supporting the agency's proposed move of cannabis from Schedule I to Schedule III.

Implementation and Physician Education Next Steps

AMA staff will now draft model state legislation for flavored-vape bans and develop continuing medical education modules on geriatric cannabis use. The resolutions also direct AMA to coordinate with the American Geriatrics Society and the American Academy of Family Physicians on joint guidance for primary-care providers.

Materials for older adults will cover dosing considerations, product-selection counseling, and screening protocols for cannabis use disorder in patients over 65. AMA expects to publish initial guidance by Q4 2026.

Policy Implications for State Medical Programs

State medical cannabis regulators may adopt AMA's flavored-vape position as clinical justification for restricting product formulations, while the geriatric resolution provides cover for physicians hesitant to recommend cannabis to older patients. For context on how medical societies influence state policy, see the CannIntel topic hub on AMA cannabis policy positions.

The resolutions carry no binding force. They do shape regulatory debates in states where medical boards reference AMA guidance. Operators in states considering flavor bans should anticipate tighter formulation rules and potential SKU restrictions in medical dispensaries.

The next AMA House of Delegates meeting is scheduled for November 2026. Cannabis-related resolutions under consideration include physician liability protections in medical programs and standards for cannabis-impairment testing in clinical settings. We'll be watching whether those measures advance and how state boards respond to the June guidance.